{"version":"1.0","provider_name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","provider_url":"https:\/\/urfaeo.kolaysoft.com.tr","author_name":"Yeni Admin","author_url":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/author\/yeniadmin\/","title":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"rcwzYJDTt4\"><a href=\"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/\">25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/embed\/#?secret=rcwzYJDTt4\" width=\"600\" height=\"338\" title=\"&#8220;25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.&#8221; &#8212; \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" data-secret=\"rcwzYJDTt4\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/urfaeo.kolaysoft.com.tr\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","thumbnail_width":1024,"thumbnail_height":768,"description":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 B\u0130LG\u0130 NOTU &nbsp; \u201c4.2.1.C-Biyolojik ajanlar\u201d ba\u015fl\u0131kl\u0131 maddesine; \u201c(5) Tan\u0131 de\u011fi\u015fikli\u011finin olu\u015fmas\u0131 halinde yeni tan\u0131da idame kriterleri ge\u00e7erlidir.\u201d f\u0131kras\u0131 eklenmi\u015ftir. &nbsp; \u201c4.2.1.C-5 -Tosilizumab\u201d etkin maddesiyle (ACTEMRA) ilgili olarak Dev h\u00fccreli arteriti tan\u0131s\u0131nda; &nbsp; -\u201cY\u00fcksek doz kortikosteroidle birlikte Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131ndan onayl\u0131 olmas\u0131 halinde methotreksat, leflunomid, azatioprinin herhangi birinin 3 ay s\u00fcre ile kullan\u0131lm\u0131\u015f olmas\u0131na ra\u011fmen yan\u0131t al\u0131namamas\u0131 durumunda.\u201d maddesi eklenmi\u015ftir. &nbsp; -Rapor ve re\u00e7ete d\u00fczenleyebilen hekimler aras\u0131ndan, \u201cAlerji uzman hekimleri\u201d \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. &nbsp; 4.2.1.C-6 maddesinde, upadasitinib etkin maddesinin (RINVOQ) \u201cUpadasitinibin Dev H\u00fccreli Arteriti (DHA) hastal\u0131\u011f\u0131nda\u201d kullan\u0131m\u0131nda geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; 4.2.1.C-9- Sekukinumab (VERXANT) maddesinde, \u201cAktif orta il\u0103 \u015fiddetli hidradenitis s\u00fcp\u00fcratival\u0131 (akne inversa) eri\u015fkin hastalarda\u201d kullan\u0131m\u0131na y\u00f6nelik geri \u00f6deme ko\u015fullar\u0131 belirlenmi\u015ftir. &nbsp; \u201cvortioksetin\u201d etkin maddeli ila\u00e7lar (FONKSERA, SORDENA); \u201cyaln\u0131zca orta veya a\u011f\u0131r depresif bozukluk tedavisinde\u201d kar\u015f\u0131lan\u0131rken, yap\u0131lan de\u011fi\u015fiklik ile geri \u00f6deme ko\u015fulu \u201cmajor depresif epizotlar\u0131n tedavisinde\u201d \u015feklinde d\u00fczenlenmi\u015ftir. &nbsp; 4.2.2 maddesinden \u201cBrekspiprazol etkin maddeli ila\u00e7lar (REXULTI) maj\u00f6r depresif bozukluk (MDD) endikasyonunda \u00f6denmez.\u201d \u0130fadesi kald\u0131r\u0131lm\u0131\u015ft\u0131r. &nbsp; DMAH\u2019lar\u0131n raporsuz olarak re\u00e7ete edilme ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, ba\u015flang\u0131\u00e7 rapor s\u00fcresi 3 aydan 6 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. 1 y\u0131l rapor s\u00fcreli devam tedavisi ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, 1 y\u0131ldan uzun s\u00fcreli kullan\u0131ma ili\u015fkin olan d\u00fczenleme 6 aya indirilmi\u015ftir. Gebelikte geri \u00f6denme ko\u015fuluna ili\u015fkin rapor s\u00fcresi 9 aydan 10 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. Raporsuz acil ve yatan hastalarda t\u00fcm hekimlerce re\u00e7ete edilmesi halinde \u00f6denmeye devam edecektir. &nbsp; Abirateron etkin maddesinin (ABIRATEX) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; \u0130ksazomib(NINLARO), karfilzomib(KYPROLIS), daratumumab(DARZALEX), isatuksimab(SARCLISA), elranatamab(ELREXFIO), selineksor(NEXPOVIO) ve pomalidomid(IMNOVID) etken maddeli ila\u00e7lar\u0131n \u00f6zel h\u00fck\u00fcmleri d\u0131\u015f\u0131nda birbirleri ile kombine olarak kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Daratumumab direnci olan hastalarda isatuksimab\u0131n, isatuksimab direnci olan hastalarda daratumumab\u0131n kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u201cisatuksimab\u201d, \u201celranatamab\u201d, \u201cselineksor\u201d ve \u201cfedratinib\u201d(INREBIC) etkin maddelerinin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u0130ki ya\u015f\u0131na kadar inek s\u00fct\u00fc ve\/veya \u00e7oklu g\u0131da protein alerjisi olan bebeklerde kullan\u0131lan t\u0131bbi mamalar i\u00e7in rapor d\u00fczenleyebilecek hekimlere \u00e7ocuk alerji uzman hekimleri eklenmi\u015ftir. &nbsp; Dan\u0131\u015ftay 10. Dairesinin 30.10.2024 tarih ve 2023\/4913 esas say\u0131l\u0131 karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; Mepolizumab(NUCALA) ve benralizumab(FASENRA) etkin maddelerinin ast\u0131m tan\u0131s\u0131nda kullan\u0131lmas\u0131na ili\u015fkin rapor ve re\u00e7ete d\u00fczenleyebilecek hekimler aras\u0131na alerji uzman hekimleri eklenmi\u015ftir. &nbsp; \u201cKombine koag\u00fclasyon fakt\u00f6r\u00fc\/protrombinkompleksi konsantreleri\u201d geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Bosentan etkin maddesini 32 mg dozunda i\u00e7eren ila\u00e7lar\u0131n pulmoner arteriyel hipertansiyonda ve Dijital \u00fclseri olan sistemik skleroz hastalar\u0131nda kullan\u0131m\u0131na ili\u015fkin geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Empagliflozin ve linagliptin etkin maddelerini kombine \u015fekilde i\u00e7eren ila\u00e7lar\u0131n (GLYXAMBI) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015f olup; Linagliptin ve empagliflozin kombinasyonunun, di\u011fer DPP-4 antagonistleri, SGLT2 inhibit\u00f6rleri ve GLP-1 analoglar\u0131 ile birlikte kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 belirtilmi\u015ftir. \u0130\u00e7 referans fiyatland\u0131rma uygulamas\u0131ndaki, grubun en ucuz ila\u00e7 bedelinin %10 fazlas\u0131na kadar\u0131 dikkate al\u0131nmas\u0131 hususundaki oran, %6 olarak g\u00fcncellenmi\u015ftir. &nbsp; Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar listesine \u0130satuksimab ve Sekukinumab etkin maddeleri eklenmi\u015ftir. &nbsp; Siklopiroks olamin \u015fampuan formlar\u0131 (LOPROX \u015eAMPUAN) i\u00e7in Ek-4\/E\u2019de yer alan re\u00e7ete edilme ko\u015fulu, aile hekimlerinin de re\u00e7ete edebilece\u011fi \u015fekilde d\u00fczenlenmi\u015ftir. &nbsp; EK-4\/F Listesinde Paliperidonun 6 ayl\u0131k depo parenteral formlar\u0131 i\u00e7in geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; 28.02.2022 tarihli Dan\u0131\u015ftay Karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; EK-4\/F Listesinde solifenasin, tolterodine-L, trospiyum, darifenasin, propiverin, fesoterodin, mirabegron, transdermal oksibutinin ile duloksetin etkin maddeleri i\u00e7in rapor \u015fart\u0131 getirilmi\u015f ve rapor d\u00fczenleyebilen hekimlere geriatri uzman hekimi eklenmi\u015ftir. &nbsp; \u0130\u00e7 referans fiyatland\u0131rma ve e\u015fde\u011fer band\u0131 uygulamas\u0131 27.11.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girmi\u015f olup, di\u011fer de\u011fi\u015fiklikler 03.12.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir. https:\/\/www.resmigazete.gov.tr\/eskiler\/2025\/11\/20251125-7.pdf"}